Many membrane-bound proteins undergo proteolytic release from the membrane, a process known as 'shedding'. Some of the processing events are carried out by enzymes of the ADAM (a disintegrin and metalloproteinase) family, which are also membrane bound. One of the most well known ADAM family members is TACE (tumour necrosis factor-␣-converting enzyme. TACE was the first ADAM family member to have a known physiological substrate, namely, precursor tumour necrosis factor-␣. Inhibitors of TACE block the release of the soluble form of this inflammatory cytokine, and are currently being studied in drug discovery projects for the treatment of arthritis. Since the discovery of TACE, physiological substrates for other ADAMs have been determined. This review focuses on the shedding events carried out by TACE and other ADAM family proteinases.
Introduction
Many membrane proteins have soluble extracellular domains that are subject to proteolytic release, a process known as 'shedding'. Membrane proteins that are subject to shedding typically have an extracellular domain anchored to the membrane by a single transmembrane segment. In Type I membrane proteins, such as the amyloid precursor protein (APP), the transmembrane segment lies near the C-terminus of the protein chain, whereas in Type II membrane proteins, such as precursor tumour necrosis factor ␣ (TNF-␣), the transmembrane segment lies near the N-terminal end of the protein chain [1] . In either case, shedding is effected by proteolytic cleavage in a 'stalk' region between the transmembrane segment and the globular extracellular domain. In principle, the cleavages associated with shedding could be carried out by any protease on the external side of the membrane. However, some proteases are tethered to the membrane, thereby effectively localizing their catalytic activity to the vicinity of susceptible membrane proteins. This review will focus specifically on shedding by the largest such class of membrane-tethered proteases, the ADAM (a disintegrin and metalloproteinase domain) family of zinc metalloproteases.
TNF-␣ provides a good example of ADAM-mediated shedding. Precursor TNF-␣ has a short N-terminal cytosolic segment, a single transmembrane segment, and a large C-terminal extracellular domain ( Figure 1 ). The soluble extracellular domain is released by cleavage in the stalk segment between Ala 76 and Val 77 . The membrane-bound, precursor TNF-␣ mediates responses by cell-to-cell contact, whereas the soluble, 'mature' TNF-␣ can be carried away from the cell to mediate a response at distant sites of action. Both forms are active and it is unclear as to what contribution each makes to disease states such as arthritis and cancer. However, the soluble form of TNF-␣ is involved in rheumatoid arthritis (RA), and is a principle mediator of sepsis and HIV cachexia [2] . The cleavage of precursor TNF-␣ is the key step in regulating the balance between the membrane-bound and soluble forms of TNF-␣. The enzyme responsible for TNF-␣ shedding, the TNF-␣-converting enzyme (TACE), has been cloned and expressed [3, 4] , and identified as a member of the ADAM family (ADAM 17).
The ADAM family
The domain structure of the ADAM family of proteins, showing the disintegrin and metalloproteinase domains [5] , is shown in Figure 2 . Full-length ADAMs are Type I membrane proteins in which the catalytic domain is localized on the extracellular side of the membrane. Most of the ADAMs have a characteristic HEXXHXXGXXH zinc-binding motif in the metalloproteinase domain, which classifies the ADAM family within the 'metzincin' superfamily [6] . This superfamily also includes matrix metalloproteases (MMPs) (see Chapter 3) and the more closely related snake venom metalloproteases (SVMPs). In those ADAMs where the full HEXXHXXGXXH motif is present, the three histidine residues ligate a catalytic zinc atom, and the glutamic acid residue promotes catalysis by positioning and activating a water molecule to attack the peptide backbone [6] . Several of the ADAM family members have mutated zinc-binding motifs, but show good sequence identity elsewhere within the disintegrin and metalloproteinase domains [5] . These ADAMs are not expected to function as proteases, but could achieve biological effects through their other domains. The disintegrin domain may be involved in adhesion, as has been shown for some SVMPs (for a review see [7] ), and may serve to recognize substrates in catalytically active ADAMs. ADAM family members have a pro domain at the N-terminal end of the protein chain. The corresponding pro domain in SVMPs 
ADAM 17 (TACE)
As discussed above, ADAM 17, which is often referred to as TACE, has been identified as the protease responsible for shedding of TNF-␣. TACE was originally purified based on its ability to process precursor TNF-␣ [3, 4] . Mouse cells with an inactivated TACE gene (TACE ⌬⌮n/⌬⌮n ) showed a marked reduction in soluble TNF-␣ production, confirming its role in vivo [3] . The TACE knockout work has also suggested a broader role for TACE in membrane protein shedding. For example, transforming growth factor ␣ (TGF-␣) release is impaired in fibroblasts that have been immortalized by ras transformation from TACE ⌬⌮n/⌬⌮n mice [12] . In addition, shedding of other cell surface molecules, such as L-selectin, the TNF receptors I and II, the interleukin-6 receptor and APP, is affected in the TACE knockout animals or cells (reviewed in [2, 11] ). The TACE ⌬⌮n/⌬⌮n knockout involves a deletion in the zinc-binding metalloprotease domain [3] . This deletion would remove the proteolytic activity of TACE, but could preserve its ability to interact with other proteins via the disintegrin domain, transmembrane segment or cytosolic tail. Thus, the tace ⌬⌮n gene product could possibly bind to and sequester other proteins that would normally be processed by TACE or other ADAMs, thereby effectively functioning as a 'dominant negative' with respect to other ADAM family proteases. This effect complicates the interpretation of knockout studies. The heterozygous TACE ⌬⌮n/ϩ knockout can help to recognize dominant negative effects [12] . In addition, peptides that correspond to the hypothesized cleavage sites can be tested directly for cleavage by TACE. The available peptide data are summarized in Table 1 . For example, while knockout studies have implicated TACE in the shedding of L-selectin [12] and APP [13] , recombinant TACE cleaves the corresponding peptides relatively slowly, compared with a precursor TNF-␣ peptide (Table 1 ). This suggests that the tace ⌬⌮n gene product is exerting a dominant negative effect, or that efficient cleavage by TACE requires protein-protein interactions not present in the peptide cleavage experiment. The use of multiple 'sheddases' with one of them being an ADAM family member, is not without precedent. APP is subject to cleavage at three general positions, ␣, ␤, and ␥, which correspond to cleavage by an ␣-secretase, a ␤-secretase and a ␥-secretase (reviewed in [14] ; see Chapter 4). The ␥-secretasemediated cleavage occurs in the membrane, while the ␤ cleavage occurs on the extracellular side of the membrane. Cleavage at the ␤-and ␥-positions generates the ␤-amyloid peptide, which accumulates in the amyloid plaques of Alzheimer's disease. The ␣-secretase cleaves near the middle of the ␤-amyloid sequence, leading to a non-amyloidogenic soluble APP␣ (sAPP␣) peptide. The ␤-secretase has been identified as a transmembrane aspartyl protease named BACE (␤-site APP-cleaving enzyme), while the ␥-secretase may be presenilin or a complex containing presenilin. The ␣-secretase has a constitutive activity as well as an activity that is regulated by protein kinase C. The knockout work described above suggested that TACE is a protein kinase C-regulated ␣-secretase. Studies with ADAM 10 (discussed below) suggest that it is also an ␣-secretase.
The structure of the catalytic domain of TACE has been determined by Xray crystallography [15] (Figure 3a ). In addition, several closely-related SVMP structures have been determined, including adamalysin II [16] (Figure 3B ) and atrolysin C. The structures of TACE, adamalysin II and atrolysin C reveal a highly conserved fold, with ␣-helices packed above and below a central ␤-sheet. Although the peripheral loops have different conformations, the core structure is generally similar to that of collagenase 1 and other MMP family members. The active-site cleft is delimited by ␤-strand 4, ␣-helix C and an additional protein chain from the C-terminal end of the catalytic domain. The substrate peptide chain is believed to bind to the cleft in an extended conformation, with an orientation that is antiparallel to that of ␤-strand 4. In this orientation, the substrate can make hydrogen bonds with ␤-strand 4 on the 'north' side of the cleft, and make additional hydrogen bonds with the protein on the 'south' side of the cleft, thereby effectively acting as an additional strand within an expanded ␤-sheet. TACE, adamalysin II, atrolysin C, and the MMPs all have a catalytic zinc atom positioned near the centre of the activesite cleft, where it can facilitate the cleavage of the scissile peptide bond. In all three ADAM-like proteases, the cleft has a deep lipophilic S1Ј pocket to accommodate the lipophilic P1Ј side-chain of the substrate (see Chapter 1, Figure 2 ). ADAM 10 is approx. 35% identical with TACE in the catalytic domain, which suggests that its catalytic domain should have a structure similar to that of TACE. The other ADAM family members have 25-40% identity with the SVMPs, suggesting that their overall structures should be similar to that of adamalysin II and atrolysin C.
ADAM 10
ADAM 10, sometimes known as MADM, was the first ADAM family member that was shown to have a proteolytic function. ADAM 10 was purified from bovine brain based on its ability to process myelin basic protein [17] . Kuzbanian (kuz), the Drosophila melanogaster homologue of ADAM 10, was identified by screening for genes involved in neuronal development. The effects on neuronal development were subsequently linked to the cleavage of Notch, a Type I transmembrane receptor that controls cell fate determination in a broad spectrum of tissues (reviewed in [18] ). Notch is thought to be activated by ligands displayed on, or possibly derived from, adjacent cells. The known ligands are Delta, Serrate and Lag 2, which are themselves Type I transmembrane proteins. Like APP, Notch is processed by different proteases at three different positions. The first cleavage reaction is performed by a furinlike protease, while the second processing event depends on kuz (in Drosophila) or ADAM 10 and/or TACE (in mammals), with the third and final cut being carried out within the membrane in a presenilin-dependent process. The first two cleavages are required to generate functional Notch, while the third cleavage occurs upon activation of Notch by its ligands, causing release of the cytosolic domain into the cytoplasm and subsequent translocation to the nucleus. The phenotype of the ADAM 10 knockout mice resembles the phenotype of the Notch knockout, supporting the idea that the second cleavage depends on ADAM 10 rather than TACE (reviewed in [2, 11] ).
As a further complication, ADAM 10 may also, or alternatively, cleave Delta, the Notch ligand. As discussed above, there is evidence that ADAM 10 and TACE both function as ␣-secretases of APP. Transfection of HEK 293 cells with ADAM 10 increases the ability of the cells to produce sAPP␣, providing further evidence that it is an ␣-secretase for APP processing. In addition, a construct of ADAM 10 carrying a point mutation in the catalytic domain, which renders it inactive, acts as a dominant negative factor, precluding release of sAPP␣ from transfected HEK 293 cells [19] . ADAM 10 can cleave a peptide containing the APP cleavage site, although the rate of cleavage is relatively low [20] , as shown in Table 2 . These results, together with the high levels of ADAM 10 found in the brain, suggest that ADAM 10 is an APP ␣-secretase.
Ephrin-A2, a well characterized axon repellant, appears to be a physiological substrate for ADAM 10 also [21] . Ephrin-A2 exists as a membrane bound form that binds Eph receptors on target cells. Ephrin-A2 binding can stimulate signalling through the tyrosine kinase domain of the receptor. However, after binding to the receptor, ephrin-A2 is processed by ADAM 10 to generate a soluble form. Since the soluble truncated form cannot activate the receptor, the cleavage process results in axon detachment and termination of signalling. A dominant negative mutant of ADAM 10 that lacked the protease domain was able to bind to ephrin-A2 and inhibit shedding of its ectodomain, and a cleavage-resistant mutant of ephrin-A2 led to greatly delayed axon withdrawal [21] . Interestingly, the Drosophila homologue of ADAM 10, kuz, was originally identified by genetic screening for proteins involved in normal axon extension.
Heparin-binding epidermal growth factor (HB-EGF), a member of the epidermal growth factor (EGF) family, which is important in cell transformation and mitogenesis, may also be a substrate for ADAM 10 [22] . Cleavage of the extracellular domain of HB-EGF generates a soluble fragment that activates the EGF receptor. In epithelial cells, this process can occur in response to lipoteichoic acid from Gram-positive bacteria, which stimulates the plateletactivating factor receptor. This receptor in turn activates ADAM 10, which leads to cleavage of HB-EGF [22] . This cleavage is part of the signalling pathway by which epithelial cells secrete mucin in response to Gram-positive bacteria. The same general ADAM-dependent pathway may be used by a variety of other G-protein-coupled receptors (GPCRs) to activate the EGF receptor in other cell types.
Considering the similarities between ADAM 10 and TACE, one might expect that ADAM 10 cleaves precursor TNF-␣. However, as shown in Tables 1  and 2 , the corresponding TNF-␣ peptide is cleaved much less efficiently by ADAM 10 than by TACE. ADAM 10 also processes precursor TNF-␣ inefficiently compared to TACE, and selective ADAM 10 inhibitors do not inhibit TNF release. Taken together, these data indicate that ADAM 10 is not a physiologically relevant TNF-␣-converting enzyme. 
ADAM 9
HB-EGF may also be a substrate for ADAM 9, a protease that is also referred to as meltrin-␥ or MDC 9 (metalloproteinase disintegrin and cysteine-rich). Izumi et al. [9] showed that overexpression of full length ADAM 9 increases HB-EGF shedding. Mutation of the HEXXHXXGXXH zinc-binding motif in ADAM 9 led to apparent dominant negative effects, although this mutation also leads to a defect in folding and transport of the protein to the cell surface, thereby complicating the interpretation. Therefore, it is unclear if these results implicate ADAM 9 as a HB-EGF-processing enzyme. ADAM 9 can also process a peptide that spans the cleavage sequence of APP, and a classical MMP substrate [10] . ADAM 9 cleaves at a site distinct from the normal ␣-secretase site that generates sAPP␣ [10] . However, this alternative cleavage does actually occur in hippocampal neurons, suggesting that ADAM 9 could possibly be a hippocampal ␣-secretase. Interestingly, ADAM 9 is localized to the cell surface, where its MMP-like substrate specificity could enable it to degrade matrix components.
ADAM 12
ADAM 12, or meltrin-␣, an enzyme that is important for myoblast fusion, was identified at the same time as ADAM 9 by Yagami-Hiromasa et al. [23] . Two forms of ADAM 12 arise from alternative splicing: a soluble form, ADAM 12-S, and a long, membrane-bound form, ADAM 12-L. An ␣-2 macroglobulin assay was used to demonstrate that ADAM 12-S is proteolytically active [24] . A substrate for ADAM 12-S, insulin-like growth factor (IGF)-binding protein 3 (IGFBP-3), was then identified through a yeast two-hybrid system when placental proteins were screened for their ability to interact with IGFBP-3 [25] . IGFBP-3 is thought to function by sequestering IGF-I or -II until they are released by proteolysis of the binding protein through the action of ADAM 12-S and/or by other processing events. The balance between the IGFs and the IGFBPs is critical in osteoarthritis and diabetes, where decreased IGF levels are associated with the disease states. As discussed above for ADAM 10, ADAM 12 has also been implicated in the processing of HB-EGF in the GPCR/EGF receptor signalling pathway [26] . In this case, certain vasoactive molecules, such as phenylephrine, angiotensin II and endothelin-1, activate specific GPCRs in cardiomyocytes. These GPCRs induce ADAM 12 activity, which leads to shedding of HB-EGF and activation of the EGF receptor. Asakura et al. [26] found that a metalloprotease inhibitor could attenuate the cardiac hypertrophy normally induced by phenylephrine and angiotensin II.
ADAM family proteases as targets in drug discovery
The membrane proteins that are subject to shedding by ADAM family proteases are involved in a number of serious diseases, and thus provide targets for drug discovery. TNF-␣ is again a convenient example, since it is responsible, in part, for the inflammation in RA. One approach to therapy involves TNF antagonists [27, 28] . For example, Enbrel ® (etanercept) is a TNF receptor fusion protein that binds TNF-␣ and effectively diverts some fraction of the endogenous TNF-␣ away from the TNF receptor on target cells. An Enbrel ® /methotrexate combination has proven to be an effective treatment for RA [27] . Remicade ® (infliximab) is a monoclonal antibody targeted against TNF-␣, which is effective in the treatment of Crohn's disease, and in combination with methotrexate, is effective in RA [28] . These protein-based therapeutics are difficult to manufacture and deliver, and small molecule antagonists that could be delivered by mouth would be preferable. While it is generally difficult to obtain small molecules that directly antagonize cytokines, it is feasible to find small molecules that inhibit TACE, thereby preventing the secretion of the soluble, mature form of TNF-␣. Non-selective TACE inhibitors have already been obtained from earlier MMP drug discovery projects, and have proven to be effective in preclinical models of septic shock and arthritis (reviewed in [2] ). Several drug companies are working towards more selective compounds. Dupont is apparently the most successful to date, with a TACE inhibitor entering clinical trials.
Conclusion
Many membrane proteins have extracellular domains that are subject to proteolytic release into the extracellular medium, a process known as shedding. Among the proteins subject to shedding are precursor TNF-␣, TGF-␣, the TNF receptors, APP and HB-EGF, which are thought to be involved in various disease processes such as arthritis, Crohn's disease, Alzheimer's disease and cardiac hypertrophy. Recent work has shown that ADAM family proteases are responsible for several of these shedding events, and evidence for their involvement in other shedding events is accumulating. ADAM family proteases are good targets for drug design, and inhibition of specific ADAM-mediated shedding processes may ultimately prove to be an effective therapy for a range of diseases. 
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